研究单位：[1]Akeso[2]Fujian Cancer Hospital,Fuzhou,Fujian,China,350000[3]Sun Yant-Sen Memorial Hospital,Guangzhou,Guangdong,China,510000[4]The Fourth Hospital of Hebei Medical University,Shijiangzhuang,Hebei,China,050000[5]Liaoning Cancer Hospital & Insitut,Shenyang,Liaoning,China,110042[6]Tianjin medical university Cancer Institut & Hospital,Tianjin,Tianjin,China,300000[7]Zhejiang Cancer Hospital,Hangzhou,Zhejiang,China,310022
This is a multicenter, open-label, phase II clinical study, aiming to the evaluate the efficacy and safety of AK104, an anti- PD-1 and CTLA-4 bispecific antibody, in subjects with recurrent or metastatic vulvar cancer not amenable to curative surgery or radiotherapy.
